In Episode 145, Fred Chong returns to discuss what's new at Infleqtion, now a public company, and the work that's keeping him busy across both academia and industry. The team dig into Quantum for Bio, a multimodal cancer biomarker discovery project developed with Welcome Leap and now continuing with IBM, where hybrid quantum-classical algorithms are uncovering relationships between genes, RNA, and tumor imaging that classical methods haven't been able to tackle. Fred shares Peter Shor's perspective that the shortage of quantum algorithms reflects a shortage of good machines, not a shortage of ideas, and why that's an optimistic take. The conversation also covers neutral atoms as a maturing modality, Infleqtion's dual-species machine and how it reduces the need for physical qubit movement, and the concept of interleaving error-corrected qubit tiles to reduce long-range communication costs.